Leading AI document intelligence platform secures new funding led by Andreessen Horowitz, bringing total funding to over $100M in less than one year

SAN FRANCISCO, Oct. 14, 2025 — Reducto, the leading AI document intelligence platform, announced a new $75M Series B funding round. The round was led by Andreessen Horowitz, with participation from existing investors Benchmark, First Round Capital, BoxGroup, and YCombinator. This follows the company’s April 2025 Series A round of $24.5M and brings Reducto’s total funding to date to $108M.

Since its founding two years ago, Reducto has pioneered a new standard for document understanding by combining traditional optical character recognition (OCR) with modern Vision-Language Models (VLMs), enabling systems to read documents as a human would. Building on that foundation, the company has continued to push the frontier of how companies interact with unstructured data with releases for advanced parsing, splitting, structured document extraction, and the industry’s first AI document editing API.

“Documents contain some of the most valuable data in most industries—from healthcare to finance to logistics. Yet until now, they’ve been a bottleneck for making AI useful for real enterprise use cases,” said Adit Abraham, co-founder and CEO of Reducto. “Our vision is to build the trusted layer that connects messy, real-world data with language models—so that AI can reason over the world as it really is, not just the text that’s clean and easy.”

Since announcing their Series A 5 months ago, Reducto’s monthly processing volume has grown by more than 6x, processing close to a billion pages of data for many of the world’s leading technical teams. Customers range from fast growing AI-native startups, including Harvey, Rogo, and Scale AI, to global financial institutions and Fortune 10 enterprises. These companies rely on Reducto to handle their most complex and mission-critical document workflow, such as, converting pdfs with redlines to text in legal workflows, extracting complex charts for financial due diligence, or high-stakes figure extraction for healthcare decisions.

“Reducto has become a magic ingredient that modern AI companies build with when it comes to large scale document workloads,” said Jennifer Li, General Partner at Andreessen Horowitz. “The team not only anticipated the rise of vision language models, they’ve continuously pushed the field forward with first-party research, elegant product experience and robust infrastructure that enterprise customers love.”

Reducto’s platform already powers the end-to-end lifecycle of unstructured data, and creates LLM-ready inputs for any use case. These capabilities are delivered through both a developer-friendly API and Reducto Studio, an interactive workspace for building, evaluating, and deploying pipelines.

Reducto is now making reliable document ingestion available to everyone building with AI. The company announced that it’s introducing a new flexible pricing structure for startups and innovators who want access to the same best-in-class infrastructure used by leading enterprises. These options lower the barrier for early-stage teams and researchers, helping them start fast today, and grow with Reducto as their dedicated ingestion team for the long run.

The $75M Series B funding will accelerate development across model research and product capabilities,  and scale the company’s adoption across both enterprise and the next generation of AI teams. “Our current customers love us for our best-in-class accuracy, and we intend to continue pushing the frontier of document intelligence for them.” said Raunak Chowdhuri, co-founder and CTO of Reducto.

“Reducto is at the inflection point every ambitious builder dreams of—where the technology is proven, the market demand is exploding, and the opportunity to make an impact is massive,” said Chetan Puttagunta, General Partner at Benchmark. “If you’ve ever wanted to join a company right as it defines a new category, this is that moment. Reducto is becoming the indispensable infrastructure layer for AI, and the people who join now will help shape how the world’s most important industries adopt this technology.”

To learn more, visithttps://reducto.ai or explore open roles at https://reducto.ai/careers.

About Reducto
Reducto  is the most accurate solution for turning complex documents into AI-ready inputs. The team from MIT built state of the art vision models that read documents like humans do, solving a critical bottleneck for AI teams working with unstructured data. Reducto enables reliable AI processing of sensitive documents like medical records and financial statements with the accuracy and reliability necessary in production environments.

Having processed over a billion pages for leading enterprises, and backed by $108M in funding, Reducto has quickly become the leading platform for AI document intelligence.

SOURCE Reducto

NEW YORK, Oct. 14, 2025 — Marble, the youth mental health company building the infrastructure layer for a new teen mental health system, today announced it has raised $15.5 million in Series A funding, led by Costanoa with participation from Town Hall Ventures and Khosla Ventures. Marble will use the funding to expand access to critical mental health care in schools across the U.S. and grow its team to accelerate innovation and impact at scale.

The youth mental health crisis has reached record levels: 1 in 10 teens attempted suicide in the past year, according to CDC data. Rates of anxiety, depression, and social withdrawal are surging, yet families face severe barriers to care. Nearly half of American youth are Medicaid members, and for many, waitlists at community clinics stretch months or even years. School counselors are often the first line of defense, but with average caseloads of 385 students, they simply can’t meet the need.

One Marble parent described her experience: “I tried literally everything I could to help my son, but I couldn’t make it happen. I searched far and wide for a therapist who accepted his Medicaid plan, but found none. The school couldn’t help me either, and my son just got worse and worse. He eventually stopped speaking to me entirely, and I grew more and more concerned about his well-being.”

Founded by Jake Sussman and Dan Ross, former co-founders of Headway, the largest adult mental health provider in the country, Marble partners directly with schools to identify students in need and connect them quickly to licensed therapists. Since launching in New York last year, Marble has facilitated more than 15,000 therapy sessions for kids and families who otherwise wouldn’t have access to care. By embedding within schools and partnering with both Medicaid and commercial payers, Marble brings evidence-based therapy to students who might otherwise struggle to access care—especially those covered by public insurance.

“In my time teaching at a low-income charter school in Brooklyn, I saw students in crisis left waiting for help, while school counselors scrambled to find support that just wasn’t there,” said Jake Sussman, Marble CEO. “We built Marble to close that gap—because kids shouldn’t have to wait for help, and schools shouldn’t have to go it alone.”

Unlike traditional solutions, Marble embeds collaboration into its platform, enabling school counselors, parents, and therapists to share insights in real time. The company also reduces the administrative burden of Medicaid through tools like its AI scribe and proprietary therapist EHR, making it easier for clinicians to participate in Medicaid networks and dramatically expanding access. Marble’s group therapy programs further increase clinician capacity, enabling therapists to support more students at once while maintaining quality of care.

“Most schools want to support their students’ mental health, but they’re stretched thin and often can’t afford to bring in help,” said Amy Cheetham, Partner at Costanoa Ventures. “What stood out about Marble is that they’ve built a model where schools don’t have to pay a dime—and still get high-quality, timely care for their students. That kind of access shouldn’t be rare, and we backed Marble because they’re making it possible at scale.”

As Marble expands nationwide, its platform is also building a powerful data advantage by combining insights from therapists, schools, and families to make its clinical products more precise, personalized, and effective over time.

To learn more, visit https://www.marblehealth.com.

About Marble
Marble Health is a tech-first mental health platform that connects students to high-quality, affordable therapy through their schools. By partnering with school counselors, Marble identifies students in need and matches them with licensed therapists, online or in person, with care covered by insurance. The platform also equips therapists with time-saving tools and enables direct collaboration between counselors and clinicians, ensuring students get the support they need, when they need it.

About Costanoa 
Costanoa exists to elevate founders building companies of consequence. We lead investments from formation through Series A in Applied AI, AI Infrastructure, Cybersecurity, National Security, and Fintech. With $2.3B AUM, we’re boutique by design—making fewer investments to deliver deeper expertise and operational support when it matters most: the early, defining stages of growth. For more information, please visit www.costanoa.vc.

Media contact: [email protected]

SOURCE Marble Health

Round Led by Ambit Health Ventures Positions Smartlens for Market Entry and Future Growth

SUNNYVALE, Calif., Oct. 14, 2025 — Smartlens, Inc., a clinical-stage ophthalmic technology company advancing next-generation glaucoma management devices, today announced the closing of an oversubscribed$5.2 million bridge round led by Ambit Health Ventures. The financing will be used to advance the FDA clearance process and prepare for an expedited market launch following clearance.

The round also included continued participation from existing investors Graphene Ventures and Boutique Venture Partners, along with new investment from Harvard Business School Alumni Angels GNY and a group of leading eye care providers.

miLens is distinguished as the world’s first electronics-free contact lens technology capable of continuous intraocular pressure (IOP) monitoring. Working seamlessly with Smartlens’ AI-powered smartphone imaging platform, miLens captures critical pressure fluctuations and enables data-driven treatment optimization. The company plans to initiate commercial activities following FDA clearance, marking a major milestone in transforming glaucoma care worldwide.

Advancing Toward Commercial Launch

Building on strong clinical progress in its multi-site U.S. pivotal trial, Smartlens has made substantial advancements in regulatory preparation, manufacturing scale-up, and clinical validation.

miLens is the world’s smallest wearable microfluidic device designed as an electronics-free soft contact lens for continuous, real-world monitoring of intraocular pressure outside of clinical settings. An independent, double-blind survey of 166 ophthalmic practitioners conducted by Market Scope showed exceptionally high interest, with 96.2% expressing intent to adopt the technology once available.miLens offers unprecedented insight for patients with glaucoma, ocular hypertension, and those requiring post-surgical intraocular pressure monitoring.

“This financing milestone strengthens our position as we advance through the FDA clearance process and prepare for commercialization,” said Savas Komban, CEO and Co-Founder of Smartlens, Inc. “We’re laying the foundation for the next generation of glaucoma management—one driven by continuous, data-based insight rather than intermittent snapshots. The continued confidence from our investors underscores both the scale of the opportunity ahead and the meaningful impact miLens can have for patients worldwide.”

Addressing a Critical Unmet Need

Together with ocular hypertension, glaucoma affects more than 180 million people worldwide and remains the leading cause of irreversible vision loss. Because elevated intraocular pressure is the primary modifiable risk factor, continuous IOP monitoring has the potential to transform glaucoma management by enabling earlier intervention and personalized therapy. Current clinical practice still relies on infrequent, single-point IOP measurements that often miss critical fluctuations throughout the day and night.

“Smartlens continues to make impressive progress with its technology, and miLens is a true leap forward in ophthalmic innovation,” said Sam Goldberger, MD, MBA, Co-Founder and Managing Partner of Ambit Health Ventures. “We are proud to lead this strategic round as the company advances through the FDA clearance process, positioning Smartlens not just for commercial launch, but to redefine continuous glaucoma monitoring and transform patient care worldwide.”

About miLens

miLens provides a non-invasive, continuous IOP monitoring solution that integrates seamlessly into clinical workflows. The platform’s AI-driven analytics deliver comprehensive pressure profiles and predictive insights, enabling personalized treatment optimization to help prevent disease progression. By offering real-world, continuous data, miLens gives ophthalmologists a new level of visibility into IOP behavior—empowering smarter, earlier, and more effective glaucoma management.

About Smartlens, Inc.

Smartlens, Inc. is an ophthalmic technology company dedicated to transforming anterior segment disease management through breakthrough innovations in continuous monitoring, diagnosis, and treatment optimization. The company’s proprietary platform combines microfluidic contact lens technology with AI-enhanced diagnostics to enable real-time, personalized glaucoma management and future applications for other ocular diseases.

For more information, visit www.smartlens.health

About Ambit Health Ventures

Ambit Health Ventures is a healthcare innovation venture capital firm specializing in early-stage digital health and medtech investments. The firm’s leadership brings deep sector expertise and provides strategic support to portfolio companies driving innovation and improved outcomes across the healthcare ecosystem.

For more information, visit www.ambithealthventures.com

SOURCE Smartlens, Inc.

ATLANTA , Oct. 14, 2025 — KOR, a fintech leader in global reporting services and trade repositories, is pleased to announce the close of its Series B funding round. The round was led by Macquarie Capital Venture Capital, with continued participation from existing investor Mosaik Partners. This investment marks a significant milestone in KOR’s journey to transform trade and transaction reporting and expand its presence across global markets.

The financing round underscores investors’ continued confidence in KOR’s vision to simplify complex compliance requirements for global derivatives and capital markets. With the Series B capital, KOR will accelerate product innovation, scale operations, and continue coverage expansion of global reporting regimes.

“This funding is a strong validation of the progress our team has made in delivering unique, highly differentiated, trusted, high-performance reporting solutions,” said Jonathan Thursby, Founder and CEO of KOR. “We’re excited to accelerate our growth and extension of the most advanced trade reporting platform through our partnership with Macquarie Capital Venture Capital.”

KOR has built momentum with launches across the US, Canada, UK, EU, and APAC. Its platform delivers accuracy, transparency, controls and operational efficiency for institutions navigating increasingly complex reporting obligations in a persistently changing regulatory environment.

The company’s rapid growth has been driven by adoption among top-tier banks, asset managers, trading platforms, and other segments who value KOR’s combination of regulatory expertise and dynamic technology. With this Series B investment, KOR will further expand its world’s best engineering and client success teams, invest in advanced reporting capabilities, and pursue new strategic opportunities.

Green Horizon Partners served as the exclusive financial advisor to KOR.

About KOR

KOR is a US-based fintech company that develops future-minded technology innovations tailored specifically for derivatives markets. KOR Reporting Inc is an operator of global licensed derivative trade repositories. KOR Financial Inc. delivers a full suite of modular services that enable market participants to meet derivatives reporting mandates with unparalleled operational efficiency, user-centric designed systems, full processing transparency, and comprehensive self-service capabilities. Founded in 2021, the KOR team comprises former trade repository heads, top domain SMEs, and technology pioneers, creating a ground-up platform specifically for trade and transaction processing.   

For more information, interested parties can visit www.korfinancial.com  

About Macquarie Capital

Macquarie Capital Venture Capital is the venture unit within Macquarie Capital, the advisory, capital markets and principal investment arm of Macquarie Group. With a successful 30-year track record of combining expertise and capital to accelerate growth, Macquarie Capital Venture Capital partners with founders and invests in early-stage companies to help build them into global, impactful businesses. Leveraging the strength of Macquarie’s balance sheet to lead funding rounds across a company’s full lifecycle, the team focuses on software companies headquartered in Australia, Israel, the United Kingdom and continental Europe that are driving innovation in cybersecurity, compliance, regulatory technology, and artificial intelligence. 

Users can visit Macquarie Capital Venture Capital’s website to learn more. 

About Mosaik Partners

Founded by industry operating executives in 2011, Mosaik Partners invests in early-stage B2B fintech companies attacking pain points in commerce and financial services. Mosaik actively leverages its operating experience to provide promising entrepreneurs with the resources and know-how they need to achieve success. The firm has made investments in the payments, software, capital markets technology, regulatory technology, and AI/big data sectors. Based in San Francisco, the team has a collective 80+ years of operating and investing experience in the financial technology sector.

More information can be found at www.mosaikpartners.com

Contact

Operations Specialist
Savannah Vukelich
KOR
[email protected] 

Photo: https://mma.prnewswire.com/media/2795785/KOR.jpg
Logo:  https://mma.prnewswire.com/media/2795784/KOR_Logo.jpg

SOURCE KOR

Financing  supports ongoing clinical operations, development, and commercialization preparation                  

HALIFAX, NS, Oct. 14, 2025 – ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced an oversubscribed US$35 million Series D financing. The round was led by new investor, J.P. Morgan Life Sciences Private Capital.  Existing investors – F-Prime, Santé Ventures, Eight Roads Ventures, and a significant undisclosed medical device company  – also participated in the round.

The proceeds of the Series D funding round will support ongoing clinical operations, prepare for the commercialization of Eye90 microspheres^®, and drive further product innovation and development. Additional funds will be used to increase the scale and scope of the Company’s manufacturing and supply chain operations to support Eye90 microspheres commercialization well into the future.

“We have been extremely impressed with the progress ABK Biomedical has made dating back to its Series B funding round in 2019,” said Joe Siletto, Managing Partner at J.P. Morgan Life Sciences Private Capital. “ABK’s development of Eye90 microspheres has been recognized by the FDA as a Breakthrough Device Designation, having the potential to more effectively treat life-threatening or irreversibly debilitating diseases or conditions. They are executing well in their Route90 FDA IDE pivotal trial, and we are excited to help support the next steps in their company’s evolution.”

“I am humbled by the outpouring of investor interest in this funding round,” said Mike Mangano, President and CEO of ABK Biomedical.  “We welcome J.P. Morgan Life Sciences Private Capital to our Board of Directors, joining our outstanding syndicate of investors. Our ABK team is a best-in-class organization and continues to achieve our product development goals for our embolic platforms while executing our FDA IDE pivotal trial. Our Route90 PIs, investigators, and research support staff are conducting the study with exceptional rigor, in what we feel will be one of the most robust data sets ever completed within the Interventional Oncology subspecialty. We’re looking forward to our Route90 study demonstrating the breakthrough promise of Eye90 microspheres, offering better care for patients with liver cancer.”

“Our investment began in 2019 and we’re proud of the progress and tremendous collaboration between ABK Biomedical and F-Prime,” said Ketan Patel, M.D., Managing Partner at F-Prime. “The advanced design of Eye90 microspheres, its novel delivery system, forward thinking supply chain, and robust data set are poised to do very well in the marketplace. It is primed to take market share, and drive market development in this Y90 radioembolization double-digit growth segment within the Interventional Oncology device market. We’re excited to build on our investment and partner with ABK in this latest funding raise.”

About ABK Biomedical, Inc.
ABK Biomedical is a company focused on researching, developing and commercializing medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. ABK Biomedical holds intellectual property in the areas of inorganic polymer microspheres and unique administration systems. The company possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing unique embolotherapy products. Eye90 microspheres^® is considered an investigational product and is not approved for use in any regulatory jurisdiction outside of approved clinical trials. 

SOURCE ABK Biomedical Inc.

With triple-digit year-over-year growth and millions of consults delivered, MDI expands its doctor-only platform and leadership team to define the future of U.S. telehealth

NEW YORK, Oct. 14, 2025 — MD Integrations (“MDI”), the only unified telehealth platform built on a nationwide, doctor-only network, today announced it has secured a $77 million investment to accelerate growth and expansion, from Updata Partners and Denali Growth Partners, alongside the appointment of Ramin Zacharia as President & COO.

Founded in 2020 by Dr. Marc Serota, a quadruple board-certified physician, MDI has delivered millions of patient consults across all 50 states for hundreds of digital health brands, helping them launch and expand into high-demand specialties such as weight management, longevity, dermatology, women’s health, allergy/immunology, men’s health, urgent care, and diagnostics.

“After helping build technology and provider networks at eight telehealth companies, I saw the need for a single solution that connects brands and their customers with high-quality care delivered only by doctors, integrated with a pharmacy network and powered by technology.” said Dr. Marc Serota, Founder & CEO. “With MDI, we’ve created a scalable, trusted platform that unites physicians, pharmacies, and diagnostics in one system. This investment enables us to accelerate innovation and set the standard for physician-led virtual care.”

MDI gives high-growth telehealth brands the speed, scalability, and workflows they need to grow, powered by a doctor-only network and an enterprise-grade, integrated ecosystem.

Key differentiators include:

• Doctor-Only Specialty Network: Every consultation is led by a board-certified MD or DO specialist for trust, continuity, and credibility.
• Streamlined Care Delivery Model: Designed to provide complete and comprehensive care, optimize speed to service, and scale throughput.
• Built-In Compliance: State-by-state guardrails embedded in workflows to stay audit-ready and protect value.
• Integrated Ecosystem: API-first platform, with purpose-built Shopify and WooCommerce integrations, plus pharmacy, fulfillment, EHR, and payments, all unified end-to-end.
• Flexible by Design: Turnkey, no-code platform or fully customizable API integrations that allow partners to bring their own tools, technology stack, and pharmacy, without compromising compliance or scale.
• Growth-Optimized Infrastructure: Informed by an expansive dataset, MDI optimizes journeys from initial onboarding to ongoing care, improving efficiency and outcomes.

With this foundation, virtual care brands can partner with MDI to launch in weeks, expand into new specialties with predesigned workflows without costly rebuilds, and scale with confidence. Physicians choose MDI because the platform is built for how they practice, driving better patient outcomes, continuity of care and long-term customer relationships for partner brands.

Continued Scale and Market Leadership in MDI’s Next Phase
“This investment accelerates MDI’s trajectory as the leading telehealth infrastructure behind healthcare’s fastest-growing and best-known brands,” said Ramin Zacharia, newly appointed President & COO of MDI. “My focus is on scaling and replicating that model with our partner-centric focus, high-quality care through our expanding physician network, and forging deeper relationships and integrations across the ecosystem.”

As U.S. telehealth enters its next phase, the stakes are rising: regulators are demanding stronger compliance, patients expect faster access, and healthcare brands are under pressure to expand beyond single-specialty offerings. Many platforms attempt to solve these challenges with shortcuts that plateau or rigid systems that become single points of failure. MDI provides a different path, end-to-end infrastructure that enables speed, quality, and compliance.

With this growth funding, MDI will continue expanding its partner and customer base with high-quality care, deepen its nationwide physician network, expand its pharmacy and diagnostics integrations, and accelerate innovation on its highly configurable, API-first platform.

“We are excited to partner with MDI, as Marc and the team have built a highly differentiated, scaled platform in the exciting and growing telehealth ecosystem,” said Braden Snyder, General Partner at Updata Partners. “MDI’s unique proposition of unifying brands with a physician-first backbone for digital health positions it to set the standard of care for how brands launch, expand, and earn lasting patient trust.”

“MDI is a high-growth leader led by a domain expert that serves many leading and notable brands that we are excited to support and grow with in this next phase,” said Jesse Lane, Founder and Managing Director at Denali Growth Partners. “Our investment will add more momentum to MDI’s mission-driven approach and innovation in the telemedicine ecosystem. We are thrilled to be a part of the journey.”

About MD Integrations
Founded in 2020 by Dr. Marc Serota, MDI is the physician-first. end-to-end telehealth platform enabling digital health brands to scale faster, operate leaner, and deliver compliant care without building clinical operations in-house. With millions of patient consults delivered across multiple specialties and all 50 states, MDI has established itself as the category-defining leader in virtual care infrastructure. Learn more at www.mdintegrations.com.

About Updata Partners
Updata Partners is a leading growth equity firm based in Washington, D.C., focused on partnering with founders and management teams of high-growth B2B software and software-driven businesses. With over $1.5 billion in committed capital, Updata combines capital and operating experience to help companies accelerate growth and success. More information is available at www.updata.com.

About Denali Growth Partners
Founded in 2021, Denali Growth Partners (“DGP”) is a Boston-based growth equity firm with more than $800 million in Regulatory Assets Under Management (“RAUM”) as of October 1, 2025. DGP partners with rapidly growing and capital-efficient businesses. The firm typically invests between $10 million and $100 million per investment. Additional information is available at www.denaligrowth.com.

Media Contact for MD Integrations
Maria Simeone
[email protected]

SOURCE MD Integrations

Pinterest, Melio, and MoneyGram are among the customers using Basis Theory’s infrastructure to control their data and unlock agentic payments.

SAN FRANCISCO, Oct. 14, 2025 — Basis Theory, the leading independent payments infrastructure company, today announced a $33 million Series B round led by Costanoa, with participation from Stage 2 Capital, Moneta VC, and continued support from Bessemer Venture Partners, Kindred Ventures, Box Group, and Offline Ventures. The funding validates Basis Theory’s strong product-market fit and will accelerate its work with agentic commerce while expanding its enterprise-grade payment vault for merchants worldwide.

With merchants seeking better ways to manage payment data across multiple payment service providers, product leaders view payments as a strategic growth lever instead of a cost center. However, building these capabilities requires navigating significant compliance and technical complexities. With Basis Theory, customers can tokenize and manage sensitive payment data—maintaining complete control over how it’s accessed within their own systems or shared with external partners.

“The payments ecosystem is changing rapidly, and merchants no longer want to be locked into rigid platforms,” said Colin Luce, Co-Founder and CEO of Basis Theory. “We’re giving control back by making payments data as accessible and programmable as any other data type so it can fuel growth, intelligence, and automation across the entire business.”

At the core of Basis Theory’s platform is a cloud-native, PCI-compliant vault that operates independently of any payment processor or orchestration layer. The vault serves as the foundation for agentic commerce, and the Agentic Commerce Consortium—a network of more than 20 companies collaborating to build the future of agent-led commerce. Led by Basis Theory, the consortium is defining the standards and infrastructure that allow AI agents to become trusted buyers, enabling merchants to participate safely in agentic commerce at scale.

“Basis Theory is at the forefront of a dramatic shift as AI reshapes e-commerce as we know it,” said Amy Cheetham, Partner at Costanoa. “By giving merchants secure, real-time control over payment data, Basis Theory enables AI agents to authorize transactions, personalize experiences, and drive autonomous purchasing. They aren’t just keeping up with the future of commerce, they’re building it.”

Basis Theory was founded in 2020 by fintech veterans Brian Billingsley, Colin Luce, and Ben Milne, whose experience spans industry leaders like Yodlee, Dwolla, and Klarna. It has more than 40 full-time employees and plans to expand its engineering, product, and go-to-market teams to unlock the next era of innovation in payments and AI-driven commerce.

To learn more about Basis Theory, visit: www.basistheory.com and www.basistheory.ai.

About Basis Theory
Basis Theory is the leading independent payment vault, built to help merchants and platforms secure, control, and utilize sensitive payment data across systems and partners. With PCI Level 1 compliance, SOC 2 certification, and a developer-first API, Basis Theory empowers customers to design their payment infrastructure however they choose with zero lock-in. Founded in 2020, the company is backed by Costanoa, Bessemer Venture Partners, Kindred Ventures, and others.

About Costanoa
Costanoa exists to elevate founders building companies of consequence. We lead investments from formation through Series A in Applied AI, AI Infrastructure, Cybersecurity, National Security, and Fintech. With $2.3B AUM, we’re boutique by design—making fewer investments to deliver deeper expertise and operational support when it matters most: the early, defining stages of growth. For more information, please visit www.costanoa.vc.

Media contact: [email protected]

SOURCE Basis Theory

$15bn AUM Investment Firm Vy Capital led the round, joins the Board of Directors

MIAMI, Oct. 14, 2025 — Today, OneImaging, the radiology platform that simplifies medical imaging for patients, providers, and employers, announces $38 million in funding. The round was led by Vy Capital, with participation from Aquiline, Sempervirens Venture Capital, XRC Ventures, Dylan Field, Balaji Srinivasan, Jon Oringer, more. OneImaging has grown 50x in less than three years and has multiple Fortune 100 customers. In the past 18 months alone, the company has partnered with employers and integrated with the largest commercial health plans to bring affordable imaging to two million people.

1 in every 2 Americans need imaging every year. It is the 2nd most-utilized service in all of healthcare, after prescription drugs, but radiology services remain expensive and inaccessible.

Physicians are routinely coerced by their hospitals’ administration to refer patients into their own hospital systems’ imaging departments, where the average MRI is priced at over $2,000 for patients, but costs 10-20% of that to deliver. These deceptively high costs can cause 37% of people to delay or skip care, resulting in significantly worse outcomes and increased downstream costs.

Meanwhile, employers are spending 50% more on their employees’ healthcare benefits than they did 10 years ago, not only facing rising bills, but also administrative headaches from prior authorization bottlenecks and surprise billing. While imaging is crucial for early diagnosis, lower long-term costs, and better outcomes, the various shortcomings of the current radiology industry have resulted in a heavily inefficient system.

OneImaging connects patients to a nationwide network of accredited imaging centers. It seamlessly manages scheduling, insurance approvals, pricing and delivery of results—enabling up to 80% cost savings while maintaining high-quality care and transparent pricing. OneImaging removes delays and complexity so patients can get the right scan at the right time and price.

This problem became personal for OneImaging founder Elan Adler, when his father waited six weeks for an MRI, only to learn that his cancer had spread by the time he was seen. “Patients are already feeling anxious and just want to know where to go—at lower costs, with quality equipment and radiologists, in-network, and with sooner appointments,” says Adler, who built OneImaging on a decade of experience across the radiology field, including roles at Siemens Healthineers and The Cleveland Clinic. “Employers are trying to manage their budgets and contain costs. We’re growing faster than ever by providing the ‘magic pill’ for making imaging more affordable for all parties.”

OneImaging saves employers and their employees up to 80% on imaging and ensures the process is easy, affordable and stress-free by offering:

• High-quality imaging network: Higher-value imaging through OneImaging’s national network of accredited partner imaging centers
• Streamlined operations: Automated end-to-end platform that removes providers’ administrative costs, lowering their operating expenses by 30%
• Price transparency: Upfront pricing that reduces up to 38% of leakage from patients who forgo care due to high, hidden costs
• Easy user experience: Smooth digital experience that decreases cancellation rates from ~25% to 1%
• Seamless reimbursement: Simple claims process, instant provider reimbursements, and simple co-payments, with financing options available, to shorten the RCM cycle from months, into real-time
• Lower costs/better outcomes downstream: 76% of Americans live with chronic conditions, that when detected early, result in lower costs and healthier, happier lives

“Until now, patients had little education or perceived choice in where they received imaging. What matters most isn’t getting a scan where your doctor happens to work, but getting it faster, knowing the upfront cost, and being able to trust the quality of the service. OneImaging is making the most powerful diagnostic tool in medicine accessible to everyone,” Adler adds.

About OneImaging
OneImaging  is the radiology platform that simplifies medical imaging for patients, providers, and employers. By connecting people to a nationwide network of accredited imaging centers, the company delivers up to 80% cost savings while ensuring high-quality care and transparent pricing. OneImaging has grown 50x in less than three years, partners with Fortune 100 employers, and integrates with the largest commercial health plans to bring affordable imaging to millions.

SOURCE OneImaging

Prezent AI raises $30 million to acquire Prezentium and redefine enterprise business communication through AI and services integration

SAN FRANCISCO, Oct. 14, 2025 — True Global Ventures (TGV) proudly announces its continued support and participation in Prezent AI’s latest $30 million funding round, accompanying the company’s strategic acquisition of Prezentium, the leading business presentation services firm in Life Sciences.

The round, led by Multiplier Capital and Nomura Strategic Ventures, with participation from True Global Ventures, Greycroft and existing investors, positions Prezent AI company at a $400 million valuation.

A New Category in Enterprise Communication

Prezent AI, founded by Rajat Mishra, is pioneering a new category at the intersection of AI, communication, and enterprise productivity.

Unlike traditional presentation tools or agencies, Prezent AI combines AI-driven automation with human creativity and services, offering Fortune 2000 enterprises a single, scalable platform to accelerate and elevate their business communication.

The acquisition of Prezentium, founded by Deepti Juturu, strengthens this vision. Together, the companies integrate AI technology and human expertise, providing enterprises with a complete “AI + services” solution that delivers outcomes faster, smarter, and more efficiently.

Transforming a $20 Billion Market

With this acquisition and funding, Prezent AI is accelerating its mission to disrupt the $20 billion global agency and consultancy market by creating the first AI + human-augmented business communication platform.

The platform enables organizations to:

• Transform complex data into business-ready presentations in minutes
• Create brand-aligned sales and Business Review decks at scale
• Integrate with enterprise workflows via APIs and presentation agents
• Build a “Company Presentation Brain” — where communication knowledge compounds over time

Investor Perspective

“The combined entity offers corporate clients far greater flexibility in how they approach business communication. They can now rely on a master presentation delivered overnight while achieving measurable productivity gains in how presentations are adapted and deployed across business lines and teams. This unique blend of AI acceleration and human expertise enables enterprises to communicate faster and at scale.” said Frank Desvignes, Founding Partner at True Global Ventures.

A Bold Vision for the Future

“Prezent AI is not just about creating slides,” said Rajat Mishra, CEO and Founder of Prezent AI. “Our north star is delivering great business communication outcomes — powered by AI acceleration and human expertise. With Prezentium joining our platform, we’re one step closer to building the complete AI-enabled communication lifecycle for enterprises.“

About Prezent AI

Prezent AI is an AI-powered business communication platform that helps enterprise teams create, optimize, and deliver high-impact presentations. Headquartered in Los Altos, California, the company serves global clients across life sciences, technology, and manufacturing, combining AI, software, and expert human services into one integrated system.

Learn more: www.prezent.ai

About True Global Ventures

True Global Ventures (TGV) is a global venture capital firm investing in serial entrepreneurs leading AI and Blockchain companies. With presence across San Francisco, New York, Paris, London, Stockholm, Dubai, Hong Kong and Singapore, TGV backs visionary founders building the next generation of transformative technology ventures.

Learn more: https://www.tgv4plus.com/

SOURCE True Global Ventures